Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
The SERENA-6 trial showed switching to an oral SERD upon ctDNA detection of an ESR1 mutation improved PFS. However, an FDA advisory committee voted against it, citing a lack of "clinically meaningful benefit" without an overall survival advantage, a crossover design, or clear quality-of-life improvement, setting a high bar for this strategy.
Related Insights
The SERENA-6 study reveals that ESR1 mutations, a key resistance mechanism, emerge steadily throughout first-line aromatase inhibitor and CDK4/6 inhibitor therapy. This finding indicates that a single ctDNA test is inadequate. Instead, a strategy of continuous, serial monitoring is necessary to detect molecular relapse in real-time, posing a new paradigm for patient management.
The SERENA-6 strategy of switching to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical progression—is a novel concept. It forces oncologists to grapple with the idea of 'molecular progression' and whether this biomarker-led switch truly alters the disease's natural history.
Despite showing a progression-free survival (PFS) benefit, oncologists advise against the SERENA-6 strategy of switching therapy upon detecting an ESR1 mutation before clinical progression. The lack of overall survival data, flawed trial comparison (PFS vs PFS2), and significant cost burdens make this approach premature for clinical practice.
The SERINA-6 trial suggests a paradigm shift: proactively switching from an AI to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical or radiographic progression—significantly improves progression-free survival and patient quality of life.
SERENNA-six pioneers a strategy where treatment is switched upon detecting an ESR1 resistance mutation in ctDNA, *before* the patient shows clinical signs of progression. This proactive, biomarker-driven approach represents a paradigm shift from reactive treatment of progressing disease.
Despite the promise of liquid biopsies for monitoring, the SERENA-6 trial revealed a significant challenge: fewer than 10% of screened patients developed a detectable ESR1 mutation. This low yield questions the efficiency and broad applicability of this serial screening strategy to guide treatment changes.
The SERINA-6 trial supports a paradigm shift: proactively screening for ESR1 mutations via blood test and switching to camisestrant upon detection, even without radiological progression. This early switch based on molecular signals nearly doubled median progression-free survival from 9 to 16 months.
The SERENA-6 trial tested a hypothesis rooted in evolutionary biology: intervening when a resistance mutation (ESR1) first appears in ctDNA, while the clone is small and less diverse, rather than waiting for clinical progression. This proactive approach aims to control resistance before it becomes dominant and harder to treat.
The SERENA-6 trial demonstrated that using ctDNA to detect ESR1 mutations and switching from an AI to an oral SERD before clinical progression significantly improves progression-free survival and quality of life. This proactive approach, while debated by the FDA, highlights a potential paradigm shift from reactive to preemptive treatment changes.
Experts are divided on switching to an oral SERD based on detecting an ESR1 mutation before radiologic progression. A key counterargument is that this is not the patient's only chance to receive the drug, and the strategy may offer less progression-free survival than waiting for clinical progression.
